Bulk Inquiry
BMS 303141
- Soluble in DMSO and EtOH
- MF: C19H15Cl2NO4S
- MW: 424.3
Description
BMS 303141 is a cell-permeable inhibitor of ATP-citrate lyase (ACL/ACLY), a metabolic enzyme that links citrate metabolism to acetyl-CoA production and lipogenesis. It reduces lipid synthesis in hepatocyte-derived cell models.
ACLY supports de novo lipid synthesis, histone acetylation substrate supply and metabolic reprogramming in cancer and metabolic disease. BMS 303141 is useful for studying lipogenesis, acetyl-CoA metabolism and ACLY-dependent cellular growth.
Key Features
- ATP-citrate lyase inhibitor
- Reported IC50: 0.13 µM in vitro
- Inhibits total lipid synthesis in HepG2 cells (reported IC50: 8 µM)
- Targets cytosolic acetyl-CoA production and lipogenesis
Applications
- Lipid metabolism and lipogenesis research
- ACLY enzyme pharmacology
- Cancer metabolism studies
- Metabolic disease and hepatic lipid synthesis assays
More Information
| Parent CAS No. | 943962-47-8 |
|---|---|
| Chemical Name | 3,5-dichloro-2-hydroxy-N-(4-methoxybiphenyl-3-yl)benzenesulfonamide |
| SMILES | C1(S(NC2C(OC)=CC=C(C3=CC=CC=C3)C=2)(=O)=O)=CC(Cl)=CC(Cl)=C1O |
| MFCD | N.A. |
| InChi | InChI=1S/C19H15Cl2NO4S/c1-26-17-8-7-13(12-5-3-2-4-6-12)9-16(17)22-27(24,25)18-11-14(20)10-15(21)19(18)23/h2-11,22-23H,1H3 |
| InChiKey | SIIPNDKXZOTLEA-UHFFFAOYSA-N |
| CID | 16747776 |
| Short Description | ACL inhibitor |
References
- JJ Li et al. 2-hydroxy-N-arylbenzenesulfonamides as ATP-citrate lyase inhibitors. Bioorg Med Chem Lett. 2007 Jun 1;17(11):3208-11.
- Z Ma et al. A novel direct homogeneous assay for ATP citrate lyase. J Lipid Res. 2009 Oct;50(10):2131-5.
- A Kinnaird et al. Metabolic control of epigenetics in cancer. Nat Rev Cancer. 2016 Nov;16(11):694-707.
Related Products
| AXON ID | NAME | FROM PRICE |
|---|---|---|
| 1762 | PNU 100480 |
From $66.00 |
| 1962 | Dalcetrapib |
From $148.50 |
| 2042 | Azithromycin |
From $55.00 |
| 2043 | Atorvastatin calcium |
From $66.00 |
| 2047 | Torcetrapib |
From $121.00 |
| 2048 | Linezolid |
From $88.00 |
| 2059 | A 922500 |
From $121.00 |
| 2063 | Clindamycin |
From $88.00 |
| 2216 | CP 346086 |
From $154.00 |
| 2276 | Atglistatin |
From $99.00 |
| 2286 | Evacetrapib |
From $137.50 |
| 2657 | MGL-3196 |
From $99.00 |
